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An increasing level of N-methyl-D-aspartate (NMDA)
receptor hypofunction within the brain is associated with
memory and learning impairments, with psychosis, and
ultimately with excitotoxic brain injury. As the brain ages,
the NMDA receptor system becomes progressively hypo-
functional, contributing to decreases in memory and
learning performance. In those individuals destined to
develop Alzheimer’s disease, other abnormalities (eg,
amyloidopathy and oxidative stress) interact to increase
the NMDA receptor hypofunction (NRHypo) burden. In
these vulnerable individuals, the brain then enters into a
severe and persistent NRHypo state, which can lead to
widespread neurodegeneration with accompanying men-
tal symptoms and further cognitive deterioration. If the
hypotheses described herein prove correct, treatment
implications may be considerable. Pharmacological meth-
ods for preventing the overstimulation of vulnerable cor-
ticolimbic pyramidal neurons developed in an animal
model may be applicable to the prevention and treat-
ment of Alzheimer’s disease.
he amino acid glutamate (Glu) plays a central
role in both the normal and abnormal functioning of
the central nervous system (CNS). Glu is recognized to
be the main excitatory neurotransmitter in the CNS,
estimated to be released at up to half of the synapses in
the brain.In addition,Glu is also an excitotoxin that can
destroy CNS neurons by excessive activation of excita-
tory receptors on dendritic and somal surfaces. Two
major classes of Glu receptors, ionotropic and
metabotropic, have been identified. Glu exerts excito-
toxic activity through three receptor subtypes, which
belong to the ionotropic family. These three receptors
are named after agonists to which they are differentially
sensitive, N-methyl-D-aspartate (NMDA), amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA),
and kainic acid (KA).Of these three,the NMDA recep-
tor has been the most extensively studied and the most
frequently implicated in CNS diseases.
1
Excessive activation of NMDA receptors (NMDA
receptor hyperfunction [NRHyper]) plays an important
role in the pathophysiology of acute CNS injury syn-
dromes such as hypoxia-ischemia, trauma, and status
epilepticus.
1,2 Recently, hyperstimulation of AMPA/KA
receptors and consequent excitotoxicity has been pro-
posed to underlie neurodegeneration in amyotrophic
lateral sclerosis (ALS,Lou Gerhig’s Disease
3,4).The role
of Glu excitotoxicity in the pathology of several other
neuropsychiatric disorders has been extensively
reviewed elsewhere
1,5 and will not be the focus of this
paper. Instead, we will focus on the consequences of






Keywords: Alzheimer’s disease; brain aging; memory; NMDA receptor; NMDA
receptor hypofunction
Author affiliations: Department of Psychiatry, Washington University School of
Medicine, St Louis, Mo, USA
Address for correspondence: John W. Newcomer, MD, Department of Psy-
chiatry, Washington University School of Medicine, 4940 Children’s Place, St




Basic researchProgressive increases in the severity of NRHypo within
the brain, which can be induced experimentally in vivo
using NMDA receptor antagonist drugs, can produce a
range of clinically relevant effects on brain function,
which are discussed below. In brief, underexcitation of
NMDA receptors,induced by even relatively low doses
of NMDA antagonist drugs, can produce specific forms
of memory dysfunction.More severe NRHypo can pro-
duce a clinical syndrome that includes core features of
psychosis.Finally,sustained and severe underexcitation
of NMDA receptors in the adult brain is associated with
a recently discovered and unconventional form of neu-
rotoxicity,with well-characterized neuropathological fea-
tures.Neuropathological changes that can be associated
with sustained NRHypo include the disruption of neu-
ronal cytoskeletons resulting in structures resembling
neurofibrillary tangles (NFTs).These NRHypo-induced
structures can occur in multiple brain regions, resem-
bling the distribution of NFTs in Alzheimer’s disease
(AD). Differences in when NRHypo or an equivalent
state is instilled in the brain (eg,early in brain develop-
ment versus during older adulthood),and differences in
the cause of the NRHypo state,can lead to differences in
clinical and neuropathological presentations, as dis-
cussed in detail elsewhere.
6,7
In the following sections, we will describe the role of
NMDA receptor function in memory, the effect of
NMDA receptor blockade on the expression of psy-
chosis, and the type of neuronal damage produced by
severe and sustained hypoactivation of the NMDA
receptor. We will then discuss the complex neural cir-
cuitry that is postulated to be perturbed as a conse-
quence of NRHypo and to underlie the expression of
some of the neuropathological and clinical features asso-
ciated with NRHypo.Next,we will discuss the evidence
for decreasing NMDA receptor function in aging, and
the role that this may play in the expression of age-
related memory decline. Finally, we describe how age-
related decreases in NMDA receptor activity may also
interact with disease-related mechanisms to contribute
to the expression of psychosis and to certain neu-
ropathological features in patients with AD.
NMDA glutamate receptors 
and memory
Hippocampal long-term potentiation
NMDA receptors are now understood to critically reg-
ulate a physiologic substrate for memory function in the
brain. In brief, the activation of postsynaptic NMDA
receptors in most hippocampal pathways controls the
induction of an activity-dependent synaptic modifica-
tion called long-term potentiation (LTP).
8,9The NMDA
receptor has been conceptualized as a synaptic coinci-
dence detector that can provide graded control of mem-
ory formation.
10-12 LTP and other forms of activity-
dependent synaptic modification share important
properties with memory function and have been postu-
lated to underlie the brain’s ability to store informa-
tion.
13,14 NMDA antagonist drugs can block both in vivo
hippocampal LTP induction and spatial learning at
intracerebral concentrations comparable to those that
block LTP in vitro.
15,16
NMDA receptors are heteromeric complexes consist-
ing of an NR1 subunit in combination with one of sev-
eral NR2 subunits,
17,18 with the NR2 subunit regulating
channel gating.
19 Gene knockout of the NMDA receptor
NR2A subunit in mice reduces both hippocampal LTP
and spatial learning.
20 NR1-NR2B complexes in vitro
have longer excitatory postsynaptic potentials than
NR1-NR2A complexes.
21 This result suggests that
increased expression of NR2B subunits and their incor-
poration into functional receptor complexes in vivo
could increase the time period for NMDA receptors to
detect synaptic coincidence,increasing synaptic efficacy
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AD Alzheimer’s disease









NRHyper NMDA receptor hyperfunction
NRHypo NMDA receptor hypofunction
PCP phencyclidine
PC/RS posterior cingulate and retrosplenial (cortex)221
and also potentially increasing memory function. Con-
sistent with this hypothesis, investigators have recently
reported that overexpression of NR2B receptor sub-
units in transgenic mice enhances the activation of
NMDA receptors, facilitating synaptic potentiation as
well as learning and memory.
22
Animal data
Some studies of NMDA antagonist drug effects on in
vivo hippocampal LTP induction have related synaptic
changes to measures of memory and learning.However,
many studies have been devoted to characterizing the
effect of NMDA receptor antagonist drugs on memory
and learning. The cognitive effects of NMDA receptor
antagonist drugs in animals provide strong support for
the proposal that decreases in NMDA receptor function
can decrease memory and learning performance. Both
competitive and noncompetitive NMDA antagonists
transiently impair spatial learning in rats
15,23-28 and cats,
24
including performance on object recognition tasks with a
major working memory component.
29 Many studies
demonstrate NMDA antagonist–induced impairments
on spatial
30-33 and nonspatial
34-38 tasks that can be affected
by hippocampal lesions. In rats, the defect in memory
function induced by NMDA antagonists involves an
impairment in the acquisition or encoding of new infor-
mation, rather than its retrieval from storage,
33,39,40 or
alternatively an impairment in the consolidation of
“short-term”memory into “long-term”memory.
41,42 Sim-
ilar NMDA antagonist–induced impairments in learning
and memory (eg, delayed matching-to-sample impair-
ments) have been reported in nonhuman primates using
ketamine, phencyclidine (PCP), and MK-801.
43-46 These
studies similarly suggest an impairment in the acquisi-
tion rather than retention of new information.
45
Human data
Subanesthetic doses of PCP selectively and noncompet-
itively act as an antagonist at NMDA receptors.
47 Early
studies of acute PCP effects on cognitive function in
humans reported transient,treatment-related reductions
in memory performance,psychomotor processing speed,
selective attention, reaction time, and weight discrimi-
nation.
48-51 Similarly, ketamine anesthesia was reported
early on to be associated with transient anterograde
amnesia.
52 While decreased memory performance has
also been reported in chronic PCP as well as ketamine
abusers,
53,54 these naturalistic reports confound acute
NMDA receptor effects and other drug and nondrug
effects associated with chronic use. Clinical adverse
events associated with PCP quickly ended the use of
this agent in humans, so that more recent studies of
NMDA antagonist effects in humans have been con-
ducted using a variety of other agents including the Food
and Drug Administration (FDA)–approved anesthetic
agent,ketamine.Ketamine,like PCP,is a noncompetitive
NMDA antagonist,but it is at least 10 times less potent




Acute subanesthetic doses of ketamine produce reliable
transient decreases in long-term,explicit,or declarative
learning and memory performance that are not
accounted for by deficits in attentional performance.
57-62
Some, but not all, investigators have also detected
decreases in sustained attentional performance
59 and
verbal fluency,
58,59,63 perhaps as a function of higher
plasma ketamine levels at the time of task performance.
Decreases in performance on long-term, explicit, or
declarative memory tasks are fully consistent with the
role of NMDA receptors in the induction of hippocam-
pal LTP and with the results of numerous animal exper-
iments. In addition, however, ketamine has also been
consistently reported to decrease performance on tasks
measuring verbal and nonverbal working memory per-
formance, involving the short-term storage and manip-
ulation of information.
59,63,64
The neuroanatomical and neurophysiological substrates
of working memory performance have been intensively
studied over the past decade,and hippocampal LTP may
not play a major role. Instead, neuronal activity in brain
regions that include dorsolateral prefrontal cortex and
cingulate cortex may play an important role in supporting
this type of memory function.
65,66 Relevant clinical neu-
roscience studies have provided new insights into the role
of NMDA receptors in regulating memory function,sug-
gesting that NMDA receptors in different brain regions
may be regulating short- versus long-term memory
processes. Results from the ongoing multidisciplinary
research effort in this area, discussed below, suggest that
NRHypo in certain brain regions can perturb a complex
neural circuit resulting in increased excitatory inputs to a
variety of neocortical targets. Some of these targets
include important cortical substrates for working memory
such as cingulate cortex. These results suggest that
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NRHypo-induced increases in unmodulated excitatory
input to cingulate cortex and resulting increases in output
could contribute to disturbances in neural networks
underlying working memory function. Future studies
should address strategies to decrease excitatory inputs to
these cortical areas as a test of the hypothesis that such
increased input underlies NRHypo-induced impairments
in function, and to further understand the regulation of
working memory in healthy and disease states.
Psychotomimetic effects of NMDA glutamate 
receptor antagonists
In the 1950s, the dissociative anesthetic, PCP, was
observed to induce a psychotic state in human sub-
jects.
67,68 The syndrome produced by PCP includes hallu-
cinations,delusions,idiosyncratic and illogical thinking,
poverty of speech and thought,agitation,disturbances of
emotion, affect, withdrawal, decreased motivation,
decreases in cognitive function, and dissociation.
48-50,69-71
However, the link to NMDA glutamate receptors was
not suspected until 30 years later when blockade of
NMDA glutamate receptors was implicated as the pri-
mary mechanism by which PCP disrupts brain func-
tion.
72,73 Hypofunction of NMDA receptors induced by
various NMDA antagonist drugs is now known to pre-
cipitate a transient psychotic state in normal sub-
jects.
58-60,62,71,74-77 Ketamine,a well-studied PCP analog still
used in human anesthesia,is known to cause emergence
reactions similar to,but not as severe as,those caused by
PCP and a clinical syndrome at subanesthetic doses that
includes mild positive,negative,and cognitive symptoms
resembling schizophrenia.
47,59,60,62 Notably, these effects
are dose-dependent and memory impairments emerge
prior to the expression of psychotic symptoms.
62
PCP and related ligands act at a “PCP” receptor
78,79
located in the ion channel of the NMDA subtype of glu-
tamate receptor to effect a noncompetitive blockade of
NMDA receptor function.
72,73 In addition,CPPene (3-[2-
carboxypiperazine-4-yl]propenyl-1-phosphonate), CPP
(3-[2-carboxypiperazin-4-yl]propyl-1-phosphonic acid),
and CGS 19755 (cis-4-[phosphonomethyl]-2-piperidine-
carboxylic acid), agents that block NMDA receptors
competitively by acting at the NMDA recognition site
outside the NMDA ion channel,have all been shown to
cause a similar PCP-like psychosis in normal human vol-
unteers.
58,74-76 When PCP and ketamine, the most exten-
sively studied of these agents, are administered to
healthy subjects,they better mimic a broad range of psy-
chotic symptoms than amphetamine, lysergic acid
diamine (LSD), barbiturates, or N,N-dimethyltrypta-
mine.
48,51,80-87 Indeed, PCP-induced psychosis can be clin-
ically indistinguishable from an acute presentation of
schizophrenia,complicating appropriate clinical care.
88,89
Additional observations have strengthened interest in
the effects of NMDA receptor function in relation to
adult-onset psychoses. Patients with schizophrenia are
unusually sensitive to pharmacological blockade of
NMDA receptors, in that administration of PCP to sta-
bilized chronic schizophrenia patients can trigger a
recrudescence of acute psychotic symptoms lasting for
up to several months.
68,90 In contrast, LSD causes only a
brief hallucinogenic state that does not appear to last
longer in schizophrenia patients than in normal healthy
subjects.
71 Another important observation is that many
adults have displayed agitation and psychotic symptoms
upon awakening from PCP- or ketamine-induced anes-
thesia,whereas pediatric patients at any age prior to ado-
lescence show little or no susceptibility to this NRHypo-
associated phenomenon.
91-95 It would appear that humans
become susceptible to NRHypo-induced psychotic reac-
tions around the same age that various adult-onset psy-
chotic syndromes (eg, schizophrenia) can begin to pre-
sent.These parallels between the drug-induced NRHypo
state and adult-onset psychoses have fueled the hypoth-
esis that an NRHypo-related mechanism may contribute
to the pathophysiology of psychosis.On the basis of this
evidence, as well as postmortem evidence of changes in
glutamate metabolism
96 and receptor expression
97,98 in
schizophrenia, several authors have recently developed
theoretical positions regarding the relative roles of
NRHypo and dopamine (DA) receptor hyperfunction
as causal factors in schizophrenia.
6,47,99-101
The NRHypo hypothesis
Recent novel approaches to the treatment and preven-
tion of drug-induced and idiopathic psychoses have
emerged from the NMDA glutamate receptor hypo-
function hypothesis.
102-106 Simply stated, the hypothesis
proposes that NRHypo, the condition induced in the
human or animal brain by an NMDA antagonist drug,
might also be viewed as a model for a disease mecha-
nism which could explain the expression of psychosis,
cognitive impairments, and certain neuropathological
findings in patients with neuropsychiatric disorders like
Basic research223
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schizophrenia and AD. The disease mechanism itself
might involve dysfunction of the NMDA receptor or
downstream effects that can be modeled by blocking
NMDA receptors.An important consequence of block-
ing NMDA receptors is excessive release of Glu
107,108 
and acetylcholine
109-111 (ACh) in multiple brain regions.It
has been proposed that this excessive release of excita-
tory transmitters and consequent overstimulation of
postsynaptic neurons might explain the cognitive and
behavioral disturbances associated with the NRHypo
state.
100,107,108 It is assumed that both genetic and non-
genetic factors can contribute to the NRHypo state,and
that NRHypo can interact with a variety of other disease
mechanisms.
Neurotoxic effects of NMDA glutamate 
receptor antagonists
In order to better understand the mechanisms underly-
ing the clinical effects of NMDA antagonist drugs and
the clinical consequences of an NRHypo state, several
research groups have begun examining the conse-
quences of drug-induced NRHypo and have shown that
one typical consequence is excessive release of Glu
107,108
and Ach
109,111 in the cerebral cortex.Therefore, a con-
certed effort is being made to understand the mecha-
nism by which NRHypo triggers excessive release of
excitatory neurotransmitters in the hope that this may
provide new insights into the pathophysiology of psy-
chosis and certain cognitive impairments.While moder-
ately increased neurotransmitter release and associated
overstimulation of postsynaptic neurons can produce
certain cognitive and psychotic symptoms,unremitting-
ly severe and chronic NRHypo and associated excitato-
ry transmitter release can lead to neurodegenerative
changes in the brain.
For research purposes,creating a drug-induced NRHypo
state in the rodent brain provides an excellent means of
identifying neuronal populations that are at risk of being
hyperstimulated and potentially injured as a conse-
quence of the NRHypo state.Described below,our find-
ings indicate that a protracted NRHypo state can trigger
neuronal injury throughout many corticolimbic brain
regions.
112,113 Presumably any of these hyperstimulated
neurons can be instrumental in producing NMDA
antagonist–induced psychotic symptoms or cognitive
impairments.In addition,this animal model provides an
opportunity to test pharmacological approaches for pre-
venting the NRHypo state from hyperstimulating and
injuring neurons. Finally, a careful analysis of the phar-
macological interventions that are protective can pro-
vide insights into the circuitry and receptor mechanisms
that mediate this pathological process.
In experimental animal studies,we have found that if the
increased release of Glu and ACh is pronounced,certain
postsynaptic neurons can develop either reversible or
irreversible morphological changes, depending on the
duration and severity of the NRHypo state.
100 Low doses
of NMDA receptor antagonist drugs, such as ketamine,
MK-801, tiletamine, PCP, CPP, and CPPene, reliably
injure certain cerebrocortical neurons.
114,116 At these
doses, the injury is confined to the posterior cingulate
and retrosplenial (PC/RS) cortex and consists of the for-
mation of intracytoplasmic vacuoles in layer III-IV pyra-
midal neurons.These changes are transient and resolve
by 24 hours.
100 While these neurons will continue to
express the 72-kDa form of heat shock protein (HSP-72)
for up to 2 weeks,
115,117 they do not become argyrophilic
(de Olmos cupric silver method) or die. In contrast,
administration of an NMDA antagonist in high dosage
or by continuous infusion for several days induces a pro-
longed NRHypo state, which causes irreversible injury
involving the death of neurons in many cerebrocortical
and limbic brain regions.
112,118-120 Large to medium-sized
pyramidal and multipolar neurons are preferentially
affected,although smaller neurons are also involved.The
full pattern of damage includes the PC/RS,frontal,tem-
poral,entorhinal,perirhinal,piriform,and prefrontal cor-
tices, the amygdala, and hippocampus.
112  At 4 hours, the
reaction in PC/RS cortex consists of intracytoplasmic
vacuole formation, but in other brain regions a spongi-
form reaction featuring edematous swelling of spines on
proximal dendrites is the most prominent cytopatholog-
ical change. At 24 to 48 hours, the affected neurons
become argyrophilic and immunopositive for HSP-72
and begin to display cytoskeletal abnormalities, includ-
ing a conspicuous corkscrew deformity of their apical
dendrites. In the 72- to 96-hour interval many of the
degenerating neurons display conspicuous fragmenta-
tion, but cytoplasmic organelles and cytoskeletal ele-
ments within the cell body and mainstem dendrites of
some cells continue to show mixed signs of viability and
degeneration for at least 10 days. Over this period, the
degenerative reaction does not elicit a robust glial or
phagocytic response and the overall appearance is one of
a subacute protracted neurodegenerative process.Neural circuitry that 
is disturbed by NRHypo
In a series of recent studies, our group
115,121-124 and oth-
ers
125-127 have found that several different classes of
drugs effectively block the PC/RS neurotoxic action of
NMDA antagonist drugs.These findings,in conjunction
with other work,
122,128,129 indicate that a surprisingly com-
plex neural circuitry is involved in NRHypo neurotox-
icity (Figure 1). In a series of recent studies,
100,128,129 we
have found that a key feature of the circuitry that
mediates the NRHypo neurotoxic process is that Glu,
acting at NMDA receptors,functions in this circuit as a
regulator of inhibitory tone.Glu accomplishes this reg-
ulatory function by tonically stimulating NMDA recep-
tors on GABAergic interneurons (GABA: gamma-
aminobutyric acid), which, in turn, inhibit excitatory
projections that convergently innervate vulnerable
cerebrocortical neurons. NMDA receptor–blocking
drugs prevent Glu from driving GABAergic inhibitory
neurons, and this results in a loss of inhibitory control
over two major excitatory projections to the cerebral
cortex, one that is cholinergic and originates in the
basal forebrain,and one that is glutamatergic and orig-
inates in the thalamus.




are driven by Glu through NMDA receptors and also
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Figure 1. To explain NMDA receptor hypofunction (NRHypo)–induced neurotoxicity of posterior cingulate and retrosplenial (PC/RS) neu-
rons, we propose that Glu acting through NMDA receptors on GABAergic, serotonergic, and noradrenergic neurons maintain
tonic inhibitory control over multiple excitatory pathways that convergently innervate PC/RS neurons. Systemic administration
of an NMDA receptor antagonist (or NRHypo produced by any mechanism) would simultaneously abolish inhibitory control over
multiple excitatory inputs to PC/RS neurons. This would create chaotic disruption among multiple intracellular second messen-
ger systems, thereby causing derangement of cognitive functions subserved by the afflicted neurons, as well as eventual degen-
eration of these neurons. This circuit diagram focuses exclusively on PC/RS neurons. However, we hypothesize that a similar dis-
inhibition mechanism and similar but not necessarily identical neural circuits and receptor mechanisms mediate damage induced
in other corticolimbic brain regions by sustained NRHypo. (+): excitatory input; (-): inhibitory input; Ach: acetylcholine; NE: nor-
epinephrine; σ : sigma binding site; 5-HT: serotonin;  2:  2 subtype of the adrenergic receptor; GA: GABAA subtype of the GABA
receptor; M3: M3 subtype of the muscarinic cholinergic receptor; non-NMDA: non-NMDA subtype of the Glu ionotropic recep-














































-perform an inhibitory function so that when NMDA
receptors are hypofunctional the inhibitory restraint con-
tributed by these elements is also lost. One final aspect
that may be quite important for understanding how dis-
inhibition of this circuitry can trigger psychotic reactions
is that the vulnerable cerebrocortical neurons are gluta-
matergic neurons that ordinarily control their own firing
by activating an NMDA receptor on a GABAergic neu-
ron in an inhibitory feedback loop. When the NMDA
receptor in this feedback loop is hypofunctional (eg,
blocked by NMDA antagonist drugs), GABAergic inhi-
bition is lost and the cerebrocortical neurons’ control over
their own firing is lost at the same time as these neurons
are being hyperstimulated by disinhibited glutamatergic
and cholinergic excitatory inputs. The expected result
under these conditions would be that the overstimulated
cerebrocortical neurons could bombard many other neu-
rons in their projection fields with unmodulated output
(ie,noise).This provides a credible hypothesis for the psy-
chotomimetic reactions and working memory impair-
ments induced by NMDA antagonist drugs, and we pro-
pose that a similar NRHypo mechanism could contribute
to the expression of psychosis and memory impairments
in a variety of neuropsychiatric disorders,including AD.
Treatment implications of 
the NRHypo circuitry model
The ability of certain classes of drugs to prevent the neu-
rotoxic consequences of the NRHypo state in rat brain
raises the question whether these drugs might also block
the psychotomimetic consequences of the drug-induced
NRHypo state in humans, or psychotic symptom forma-
tion in certain neuropsychiatric disorders. Information
pertaining to this question,although incomplete,provides
some interesting correlations. Agents that promote
GABAA neurotransmission prevent the NRHypo state
from releasing excessive Ach
129 (Figure 1) and prevent
NRHypo neurotoxicity in the rat cerebral cortex,
123 and it
is well recognized by anesthesiologists that these agents in
sufficient dosage attenuate the psychotomimetic actions
of ketamine.
91 α 2-Adrenergic agonists prevent the NRHy-
po state from releasing excessive acetylcholine
129 (Figure
1) and prevent NRHypo neurotoxicity in the rat cerebral
cortex,
123 and it was recently shown that an α 2-adrenergic
agonist can prevent ketamine from inducing positive
schizophrenia-like symptoms in normal human volu-
teers.
103 Lamotrigine, an agent that may inhibit the exces-
sive release of Glu at non-NMDA receptors (Figure 1),
prevents NRHypo neurotoxicity in the rat cerebral cor-
tex
131 and was recently shown to prevent ketamine-
induced schizophrenia-like symptoms in human volu-
teers.
104 Clozapine and olanzapine, which are effective
drugs for treating schizophrenia, are also quite potent in
blocking NRHypo neurotoxicity in the rat cerebral cor-
tex,
132 and clozapine has been reported to block ketamine-
induced increases in positive symptoms in patients with
schizophrenia.
133
Age-related decreases in NMDA
receptor function may explain age-related
decreases in memory 
At least four different laboratories studying three dif-
ferent nonhuman species (mice, rats, and monkeys)
have reported that the NMDA receptor transmitter sys-
tem becomes markedly hypofunctional with advancing
age.
134-138 Several different age-related changes can con-
tribute to this decrease in function (for a review see
reference 138).The most consistently reported decrease
in binding parameters has been an age-related decrease
in binding to the NMDA site,using agonists and antag-
onists, in the neocortex and hippocampus of rodents
and primates. Depending on the species, this generally
appears to reflect a decrease in the number of binding
sites, rather than changes in affinity, and generally
reflects greater decreases in the cortex than in the hip-
pocampus. Variable age-related changes in binding to
the glycine site have been observed. Age-related
decreases in binding to the PCP site have also been
observed across multiple species, again greater in the
neocortex than the hippocampus. This again generally
appears to reflect decreases in the number of binding
sites, rather than changes in affinity. In humans, a 36%
decrease in Bmax for [
3H]MK-801,reflecting a decreased
number of PCP binding sites, was observed comparing
10 to 20 year olds and individuals in their 90s.
139
NMDA receptor subunit expression also changes with
aging.NR1 expression has been reported to be decreased
in the dentate of aged macaques
140 and in the cortex and
hippocampus of rodents.
141 NR2B expression also
decreases with aging in the hippocampus and cortex of
rodents.
142,143 It should be recalled that NR1-NR2B com-
plexes in vitro demonstrate longer excitatory postsynap-
tic potentials than NR1-NR2A complexes
21 and that an
increased presence of NR1-NR2B complexes in vivo
NMDA receptor function,memory,and brain aging - Newcomer et al Dialogues in Clinical Neuroscience - Vol 2 . No.3 . 2000
225could increase the time period for NMDA receptors to
detect synaptic coincidence,potentially increasing synap-
tic efficacy and memory function. Thus, an age-related
decrease in NR2B expression could account for age-
related shortening of the excitatory postsynaptic potential
duration of the NMDA channel.
144,145As mentioned above,
overexpression of NR2B receptor subunits in transgenic
mice enhances the activation of NMDA receptors,facili-
tating synaptic potentiation as well as learning and mem-
ory.
22 This overexpression has also been reported to pre-
vent age-related decreases in memory and learning
performance. These results support the hypothesis that
age-related decreases in NMDA receptor function could
account for age-related decreases in memory and learn-
ing. This suggests that strategies to prevent those age-
related changes, or strategies to prevent downstream or
other events related to those changes,could have impor-
tant therapeutic implications for the prevention or treat-
ment of age-related memory impairments.
NRHypo hypothesis of AD
In addition to age-related increases in NRHypo, it was
recently shown in humans that a more severe degree of
NRHypo is present in the AD brain than in age-
matched normal controls.
97 Thus, in the aging human
brain the stage may already be set for widespread corti-
colimbic neurodegeneration to occur. All that is
required to explain why it occurs to a more severe
degree in the AD brain than in the “normal”aging brain
is to identify one or more adjunctive conditions peculiar
to the AD brain that may serve as catalysts or promot-
ers of the NRHypo state. In our animal model of
NRHypo using otherwise healthy brain,no evidence of
amyloidosis or amyloid plaque formation is observed.
Therefore, we propose that genetic or other predispos-
ing factors peculiar to the AD condition are primarily
responsible for the amyloidopathy in the AD brain and
that when amyloidopathy occurs alongside NRHypo,
the pathological process known as AD develops. How
then does amyloidosis interact with NRHypo?
Over the past decade, major strides have been made in
discovering important genetic abnormalities in AD.
Mutations on four different chromosomes,each of which
can promote amyloidopathy, have now been identified
as etiologic factors in familial AD and the role of apoE
genotype as a risk factor in sporadic AD has been estab-
lished. While recent research has elucidated the basic
neurochemistry of beta-amyloid and it is clear that
abnormal deposition of beta-amyloid in the brain occurs
early in AD,it is not at all clear how beta-amyloid depo-
sition contributes to the neurodegenerative events in
AD.Based on evidence that a severe degree of NRHypo
is present in the human AD brain, that NRHypo can
induce an AD-like pattern of neurodegeneration in ani-
mal brain, and that beta-amyloid deposition may con-
tribute to a worsening of the NRHypo state,we propose
NRHypo as a missing link that can help explain major
aspects of the pathophysiology of AD that have, until
now,remained elusive.
Similarities between the neuronal 
degeneration seen in NRHypo and in AD
There are important similarities between the overall pat-
tern of NRHypo neurodegeneration and the pattern that
has been described in the AD brain by various
researchers.The PC/RS cortex, which is the brain region
most vulnerable to NRHypo degeneration, was recently
reported to be selectively affected early in the course of
AD in a PET study of living patients.
146The PC/RS cortex
has also been shown to be markedly atrophic late in the
disease.
147 In contrast, neurodegeneration in the anterior
cingulate cortex is less severe in both the AD brain
148 and
the NRHypo animal model.While it is difficult to make
precise anatomical comparisons between the rodent and
human brain,the transentorhinal area,considered among
the earliest and most severely affected regions in the
human AD brain,
149 is roughly homologous to the perirhi-
nal cortex in rat brain,which is second only to the PC/RS
cortex in its sensitivity to NRHypo neurodegeneration.
Other brain regions preferentially affected in both the
AD brain and the NRHypo model include portions of
the parietal,temporal,entorhinal,amygdaloid,subicular,
hippocampal, and insular cortices. A mild but transient
microglial and astrocytic response accompanies the neu-
rodegeneration seen with NRHypo.However,consistent
with the known pathology of AD, a robust phagocytic
response is conspicuously absent.
150
The neurons primarily involved in neurofibrillary tangle
(NFT) formation in the AD brain are distributed widely
throughout cortical and limbic brain regions,but in each
region these neurons tend to be pyramidal or multipolar
neurons and in certain cortical regions they are distrib-
uted in a bilaminar pattern.This fits the description of




in the cerebral cortex are also occasionally involved but
the most prominently affected neurons are medium-
sized pyramidal or multipolar neurons in each region.
The tortuousity of dendritic processes in the NRHypo
model is accompanied by a parallel pattern of tortuosity
of the microtubular cytoskeleton within the distorted
dendrite.This suggests that changes in the external con-
figuration of the dendrite are due to cytoskeletal changes
within the dendrite.The cytoskeleton of the injured neu-
rons appears to be undergoing both degenerative and
regenerative processes, but the repair effort is not very
successful.As described above the mechanism of injury
involves simultaneous hyperactivation of the neuron
through several excitatory receptors, including a mus-
carinic (M3) cholinergic receptor and a glutamatergic
(non-NMDA) receptor (Figure 1). Second messenger
systems associated with the KA receptor are not known
at this time, but it is well known that the M3 muscarinic
receptor is coupled to a phosphoinositide/Ca
2+/protein
kinase C second messenger system that mediates protein
phosphorylation functions.Thus, the erratic pattern of
microtubule tortuosity and disarray together with appar-
ent efforts at microtubule regeneration may reflect
abnormal hyperactivity of this M3-linked second mes-
senger system and consequent disruption of its protein
phosphorylation functions.Since other unknown second
messenger systems are also hyperactivated simultane-
ously in the same neuron, these systems may also con-
tribute to the cytoskeletal disruption pattern.
Neurofibrillary tangles and psychosis 
could be associated through NRHypo
We are beginning to study the possible relationship
between this cytoskeletal disruption process in the
NRHypo model and NFTs, its potential counterpart in
the AD brain.Thus far, we have not detected ultrastruc-
tural evidence of paired helical filaments. Even if such
evidence cannot be found,this might signify species speci-
ficity of this particular abnormality without disqualifying
the NRHypo degenerative process as a valid model of the
mechanism giving rise to NFT in the human AD brain.
Thus, our findings in the rat are consistent with the con-
clusion that NRHypo alone can produce many of the
neuropathological features of AD.The observations that
NRHypo can produce psychotic symptoms, as well as
potentially contribute to NFT formation,suggest that psy-
chosis could be associated with NFT burden in AD
patients.We recently tested this hypothesis in a post-
mortem sample of AD patients and found that,after con-
trolling for the severity of dementia, neocortical NFT
counts were increased in patients with AD who experi-




Most investigators of amyloidosis have tended to focus
exclusively on the potential of beta-amyloid to kill neu-
rons by itself without reference to its potential patholog-
ical interaction with NMDA receptors.We think the focus
should be redirected. Beta-amyloid alone is not toxic
except at very high concentrations, whereas at substan-
tially lower concentrations beta-amyloid causes cultured
neurons to become hypersensitive to Glu or NMDA exci-
totoxicity.
152-154 We propose, therefore, that predisposing
factors (eg, apoE4 genotype in sporadic AD, amyloido-
genic mutations in familial AD) promote amyloidosis
which, in turn, increases the sensitivity of NMDA recep-
tors so that even normal concentrations of Glu can trigger
abnormal currents,which on a chronic low-grade excito-
toxic basis can destroy NMDA receptor–bearing neurons.
Loss of these neurons and their NMDA receptors
increases the NRHypo burden in the aging brain.
Other factors such as oxidative stress and disturbances in
energy metabolism may also contribute to beta-amyloid’s
augmentation of neuronal sensitivity to Glu.Disturbances
in energy metabolism may cause NMDA receptor hyper-
sensitivity by interfering with a voltage-dependent mecha-
nism by which Mg
2+ normally inhibits passage of sodium
and calcium currents through the NMDA receptor chan-
nel. Because membrane polarization is maintained by
energy-dependent mechanisms, impaired energy can trig-
ger partial membrane depolarization,which abolishes the
Mg
2+ block and allows normal concentrations of transmitter
Glu to drive abnormal currents on a chronic basis.Oxida-
tive stressors may act through a similar mechanism,in view
of evidence that free radical generation in nitric oxide path-
ways disrupts glycolytic metabolism,and superoxide radi-
cal formation causes hyperactivation of NMDA receptors
in cultured neurons.The proposal that oxidative stress may
contribute to neurodegeneration in AD is consistent with
recent evidence
155 that antioxidant drugs may retard the
progression of cognitive deterioration in AD. Whether
impaired energy or oxidative stressors are relatively more
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not clear at this time. Their presence, even if not more
severe than that in the normal aging brain,would augment
amyloid’s ability to sensitize neurons to Glu’s excitotoxic
potential. Persistent hyperactivation of NMDA receptors
would result in either excitotoxic degeneration of the den-
dritic spines on which NMDA receptors are located or in
degeneration of the entire NMDA receptor-bearing neu-
ron.In either case,NMDA receptors are deleted from the
brain and the NMDA receptor system is reduced to a
hypofunctional status. NRHypo thus could represent a
residual deficit condition caused by NRHyper.
AD neurodegeneration: 
a two-stage process
A major tenet of our proposal is that the NMDA recep-
tor system becomes hypofunctional in either the normal
brain or the AD brain after having first gone through an
early stage of NRHyper.This hypothesis,consistent with
the bulk of available data, assumes that the pattern of
massive neurodegeneration in AD tends to follow the
pattern of NFT formation,and that the neurons that dis-
play NFT at the time of autopsy are injured neurons that
would be destined to slowly die and leave behind neu-
rofibrillary debris.However,this hypothesis also assumes
that there is a less massive pattern of neuronal degener-
ation that corresponds to the pattern of amyloid deposi-
tion. Our hypothesis suggests that the neurodegenera-
tive events in AD occur in two separate stages, by two
separate mechanisms,and according to two separate pat-
terns. These have been difficult to tease apart because
the two stages have a significant degree of temporal over-
lap and the two patterns have significant spatial overlap.
We propose that the first neurodegenerative stage
entails the deposition of low concentrations of amyloid
in the brain and interaction of amyloid with certain
NMDA receptors in a manner that increases the sensi-
tivity of these receptors to Glu so that the neurons bear-
ing these receptors will be hyperstimulated and
destroyed by endogenous Glu.As these neurons degen-
erate, amyloid plaques may form and incorporate por-
tions of the degenerating neurons and other neural and
glial processes in the immediate environment.The pat-
tern of these early neurodegenerative and reactive
events will follow the pattern of distribution of the spe-
cific neurons vulnerable to this amyloid/NMDA recep-
tor–mediated neuropathological process. We postulate
that it may not be a very conspicuous pattern of neu-
ronal loss because it may be restricted to just the
NMDA receptor–bearing neurons in our schematic cir-
cuit that control the release of transmitters onto the vul-
nerable pyramidal neuron (Figure 1).In stage I,the neu-
rodegenerative process may produce few if any
symptoms,because it is limited to a small population of
neurons. In addition, we postulate that the recurrent
collateral feedback loop (Figure 1) remains relatively
intact so that pyramidal neurons, as they begin to
receive excessive stimulation, will be prevented from
firing erratically onto other neurons and thereby pre-
vented from generating florid symptoms.
The second stage commences when the loss of NMDA
receptor–bearing neurons is sufficient to substantially
unleash the disinhibition syndrome in which many pri-
mary cerebrocortical and corticolimbic neurons are
pathologically hyperstimulated through several signal
transduction pathways at the same time. At this point,
psychosis and NRHypo-related cognitive disturbances
could become evident.We propose that pyramidal neu-
rons in many cortical and limbic brain regions will be
affected,and will slowly degenerate and die as the stage II
process progresses.Death and deletion of these neurons
will disrupt mental functions just as excessive hyperacti-
vation of these neurons will disrupt these functions.
While these neurons are degenerating,we propose that
at least some of them develop NFTs on the basis of
excessive activation of second messenger pathways asso-
ciated with muscarinic and/or non-NMDA glutamate
receptors.These second messenger systems are coupled
to kinases or other possible factors relevant to protein
phosphorylation;therefore,hyperactivation of these sys-
tems provides a rational explanation for NFT forma-
tion,which is believed to result from hyperphosphoryl-
ation of microtubule-associated proteins. In stage II,
neurodegeneration occurs as a network disturbance.The
pattern of degeneration is determined by the pattern of
connections within the network, and by the failure of
inhibition over certain excitatory pathways within the
network, causing specific cortical and limbic neurons
innervated by these excitatory pathways to degenerate.
This provides a rational explanation for the pattern of
degeneration seen in AD.❑
Basic research
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La función del receptor NMDA, la memoria
y el envejecimiento cerebral
La acentuación de la hipofunción del receptor N-
metil-D-aspartato (NMDA) en el cerebro se ha
asociado con deterioro en la memoria y el apren-
dizaje, con psicosis y, últimamente con daño exi-
totóxico. Así como el cerebro envejece, el sistema
de receptores NMDA progresivamente se torna
hipofuncional, lo que contribuye a una disminu-
ción de los rendimientos de memoria y aprendi-
zaje. En aquellos individuos vulnerables para
desarrollar la enfermedad de Alzheimer hay
otras anormalidades (como amiloidopatías y el
estrés oxidativo) que interactúan para aumentar
la carga de la hipofunción del receptor NMDA.
En estos individuos vulnerables, el cerebro entra
en un severo y persistente estado de hipofunción
del receptor NMDA, el cual puede conducir a una
neurodegeneración generalizada, con síntomas
mentales asociados y a un posterior deterioro
cognitivo. Si se demuestra que la hipótesis des-
crita previamente es correcta, las implicancias
terapéuticas de ella pueden ser considerables.
Los métodos farmacológicos para prevenir la
sobreestimulación de neuronas piramidales cór-
tico-límbicas vulnerables desarrolladas en un
modelo animal pueden ser aplicables a la pre-
vención y al tratamiento de la enfermedad de
Alzheimer.
Fonction des récepteurs du NMDA, 
mémoire et vieillissement cérébral
L’augmentation de l’hypofonctionnement des
récepteurs du N-méthyl-D-aspartate (NMDA) dans
le cerveau est associée à des troubles de la mémoi-
re et de l’apprentissage, qui s’accompagnent de
psychose et évoluent vers des lésions cérébrales
excitotoxiques. Lors du vieillissement cérébral, le
système des récepteurs du NMDA devient pro-
gressivement hypofonctionnel, contribuant à la
diminution des performances mnésiques et d’ap-
prentissage. Chez les individus prédisposés à déve-
lopper une maladie d’Alzheimer (MA), d’autres
anomalies (telles que les amyloïdopathies et le
stress oxydatif) interagissent pour augmenter le
degré d’hypofonctionnement (NRHypo) des récep-
teurs du NMDA. Chez ces individus fragiles, le cer-
veau s’installe alors dans un état d’hypofonction-
nement permanent et sévère qui peut conduire à
une neurodégénération étendue associée à des
symptômes mentaux et d’autres détériorations
cognitives. Si les hypothèses décrites ici s’avèrent
exactes, les implications thérapeutiques pour-
raient être considérables. Les méthodes pharma-
cologiques de prévention de l’hyperstimulation
des neurones corticolimbiques vulnérables, déve-
loppées dans des modèles animaux, pourraient
s’appliquer à la prévention et au traitement de la
maladie d’Alzheimer.
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